OncoMatch/Clinical Trials/NCT05802121
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Is NCT05802121 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Apple Cider Vinegar for prostate cancer.
Treatment: Apple Cider Vinegar — The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage TANY, NANY (TNM)
Metastatic disease required
TNM stage Tany, Nany, M1
Demographics
Prior therapy
Cannot have received: androgen deprivation therapy
Lab requirements
Liver function
Inadequate liver function (>2x upper limit of normal) excluded
Inadequate liver function (>2x upper limit of normal)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05802121 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage TANY or NANY is required (metastatic disease required).
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages